Last updated on March 2020

A Study of Long-term Baricitinib (LY3009104) Therapy in Atopic Dermatitis

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Dermatitis | Eczema (Atopic Dermatitis) | Atopic | Eczma (Dermatite Atopique) | Dermatite Atopique | Hand Dermatitis | ATOPIC DERMATITIS
  • Age: Between 18 - 100 Years
  • Gender: Male or Female

Inclusion Criteria:

  • Have completed the final active treatment visit for an originating study eligible to enroll participants directly into study BREEZE-AD3 OR
  • Meet criteria for NCT03334396 or NCT03334422.

Exclusion Criteria:

  • Had investigational product permanently discontinued at any time during a previous baricitinib study.
  • Had temporary investigational product interruption continue at the final study visit of a previous baricitinib study and, in the opinion of the investigator, this poses an unacceptable risk for the participant's participation in the study.

Recruitment Status: Closed

Brief Description Eligibility Contact Research Team

Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.